STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDDan Turner, Axel Dignaß, Jean‐Frédéric Colombel et al.|Gastroenterology|2021Cited by 2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetLaurent Peyrin‐Biroulet, William J. Sandborn, Bruce E. Sands et al.|The American Journal of Gastroenterology|2015Cited by 1.8k
Global evolution of inflammatory bowel disease across epidemiologic stagesLindsay Hracs, Shinji Okabayashi, Joseph W. Windsor et al.|Nature|2025Cited by 294
Gut microbiota density influences host physiology and is shaped by host and microbial factorsEduardo J. Contijoch, David A. Greenwald, Graham J. Britton et al.|eLife|2019Cited by 181
Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and miceLin Wang, Spencer A. Freeman, Dominik Aschenbrenner et al.|Nature Genetics|2021Cited by 106